Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Rapamycin inhibits IGF-1-mediated up-regulation of MDM2 and sensitizes cancer cells to chemotherapy.

Du W, Yi Y, Zhang H, Bergholz J, Wu J, Ying H, Zhang Y, Xiao ZX.

PLoS One. 2013 Apr 30;8(4):e63179. doi: 10.1371/journal.pone.0063179.

2.

Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.

Thimmaiah KN, Easton J, Huang S, Veverka KA, Germain GS, Harwood FC, Houghton PJ.

Cancer Res. 2003 Jan 15;63(2):364-74.

3.

Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells.

Kao CL, Hsu HS, Chen HW, Cheng TH.

Cancer Lett. 2009 Dec 28;286(2):250-9. doi: 10.1016/j.canlet.2009.05.031.

PMID:
19560264
5.

Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.

Wang X, Yue P, Chan CB, Ye K, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Fu H, Khuri FR, Sun SY.

Mol Cell Biol. 2007 Nov;27(21):7405-13.

7.

Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.

Jhanwar-Uniyal M, Gillick JL, Neil J, Tobias M, Thwing ZE, Murali R.

Adv Biol Regul. 2015 Jan;57:64-74. doi: 10.1016/j.jbior.2014.09.004.

PMID:
25442674
8.

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR.

Cancer Res. 2005 Aug 15;65(16):7052-8.

9.
10.

mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels.

Goudarzi KM, Nistér M, Lindström MS.

Cancer Biol Ther. 2014;15(11):1499-514. doi: 10.4161/15384047.2014.955743.

11.

[Impact of PI3K /Akt /mdm2 signaling pathway on the sensitivity of gastric cancer cell line SGC7901 to doxorubicin].

Ai YW, Yu HG, Yu JP, Yang Y, Li H, Hu XW, Luo HS.

Zhonghua Zhong Liu Za Zhi. 2008 Jul;30(7):494-7. Chinese.

PMID:
19062713
13.

Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway.

Liu L, Chen L, Luo Y, Chen W, Zhou H, Xu B, Han X, Shen T, Huang S.

PLoS One. 2010 May 11;5(5):e10578. doi: 10.1371/journal.pone.0010578.

14.

PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells.

Zhou M, Gu L, Findley HW, Jiang R, Woods WG.

Cancer Res. 2003 Oct 1;63(19):6357-62.

15.

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.

Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P, Hanaoka N, Konopleva M, Andreeff M, Nakakuma H.

Leukemia. 2008 Sep;22(9):1728-36. doi: 10.1038/leu.2008.158.

PMID:
18548093
17.

Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling.

Martin KA, Merenick BL, Ding M, Fetalvero KM, Rzucidlo EM, Kozul CD, Brown DJ, Chiu HY, Shyu M, Drapeau BL, Wagner RJ, Powell RJ.

J Biol Chem. 2007 Dec 7;282(49):36112-20.

18.

Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.

Nagata Y, Takahashi A, Ohnishi K, Ota I, Ohnishi T, Tojo T, Taniguchi S.

Int J Oncol. 2010 Oct;37(4):1001-10.

PMID:
20811722
19.

Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells.

Xu Z, Zhang Y, Jiang J, Yang Y, Shi R, Hao B, Zhang Z, Huang Z, Kim JW, Zhang G.

BMC Cancer. 2010 Apr 27;10:161. doi: 10.1186/1471-2407-10-161.

20.

Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity.

Liu L, Luo Y, Chen L, Shen T, Xu B, Chen W, Zhou H, Han X, Huang S.

J Biol Chem. 2010 Dec 3;285(49):38362-73. doi: 10.1074/jbc.M110.141168.

Supplemental Content

Support Center